guest ::
| Home > Publications database > A diagnostic phase III/IV seamless design to investigate the diagnostic accuracy and clinical effectiveness using the example of HEDOS and HEDOS II. > print |
| Home > Publications database > A diagnostic phase III/IV seamless design to investigate the diagnostic accuracy and clinical effectiveness using the example of HEDOS and HEDOS II. > print |
| 001 | 287651 | ||
| 005 | 20240328132827.0 | ||
| 024 | 7 | _ | |a 10.1177/09622802241227951 |2 doi |
| 024 | 7 | _ | |a pmid:38327081 |2 pmid |
| 024 | 7 | _ | |a 0962-2802 |2 ISSN |
| 024 | 7 | _ | |a 1477-0334 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2024-00294 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Pepić, Amra |0 0000-0002-9266-4554 |b 0 |
| 245 | _ | _ | |a A diagnostic phase III/IV seamless design to investigate the diagnostic accuracy and clinical effectiveness using the example of HEDOS and HEDOS II. |
| 260 | _ | _ | |a London [u.a.] |c 2024 |b Sage |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1711628861_22852 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2024 Mar;33(3):433-448 |
| 520 | _ | _ | |a The development process of medical devices can be streamlined by combining different study phases. Here, for a diagnostic medical device, we present the combination of confirmation of diagnostic accuracy (phase III) and evaluation of clinical effectiveness regarding patient-relevant endpoints (phase IV) using a seamless design. This approach is used in the Thyroid HEmorrhage DetectOr Study (HEDOS & HEDOS II) investigating a post-operative hemorrhage detector named ISAR-M THYRO® in patients after thyroid surgery. Data from the phase III trial are reused as external controls in the control group of the phase IV trial. An unblinded interim analysis is planned between the two study stages which includes a recalculation of the sample size for the phase IV part after completion of the first stage of the seamless design. The study concept presented here is the first seamless design proposed in the field of diagnostic studies. Hence, the aim of this work is to emphasize the statistical methodology as well as feasibility of the proposed design in relation to the planning and implementation of the seamless design. Seamless designs can accelerate the overall trial duration and increase its efficiency in terms of sample size and recruitment. However, careful planning addressing numerous methodological and procedural challenges is necessary for successful implementation as well as agreement with regulatory bodies. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Seamless design |2 Other |
| 650 | _ | 7 | |a adaptive design |2 Other |
| 650 | _ | 7 | |a diagnostic accuracy |2 Other |
| 650 | _ | 7 | |a external controls |2 Other |
| 650 | _ | 7 | |a power prior |2 Other |
| 700 | 1 | _ | |a Stark, Maria |b 1 |
| 700 | 1 | _ | |a Friede, Tim |0 0000-0001-5347-7441 |b 2 |
| 700 | 1 | _ | |a Kopp-Schneider, Annette |0 P:(DE-He78)bb6a7a70f976eb8df1769944bf913596 |b 3 |u dkfz |
| 700 | 1 | _ | |a Calderazzo, Silvia |0 P:(DE-He78)b5d9469407737829d5348adb615655c6 |b 4 |u dkfz |
| 700 | 1 | _ | |a Reichert, Maria |b 5 |
| 700 | 1 | _ | |a Wolf, Michael |b 6 |
| 700 | 1 | _ | |a Wirth, Ulrich |b 7 |
| 700 | 1 | _ | |a Schopf, Stefan |b 8 |
| 700 | 1 | _ | |a Zapf, Antonia |0 0000-0002-8467-0508 |b 9 |
| 773 | _ | _ | |a 10.1177/09622802241227951 |g p. 09622802241227951 |0 PERI:(DE-600)2001539-2 |n 3 |p 433-448 |t Statistical methods in medical research |v 33 |y 2024 |x 0962-2802 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:287651 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)bb6a7a70f976eb8df1769944bf913596 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)b5d9469407737829d5348adb615655c6 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a National-Konsortium |0 StatID:(DE-HGF)0430 |2 StatID |d 2023-10-22 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-22 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-22 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b STAT METHODS MED RES : 2022 |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-22 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-22 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2023-10-22 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l C060 Biostatistik |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|